{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:00:21Z","timestamp":1788051621435,"version":"build-2784847793"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,11,15]],"date-time":"2011-11-15T00:00:00Z","timestamp":1321315200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1007\/s00210-011-0702-2","type":"journal-article","created":{"date-parts":[[2011,11,14]],"date-time":"2011-11-14T06:28:45Z","timestamp":1321252125000},"page":"313-323","source":"Crossref","is-referenced-by-count":6,"title":["Discovery of potential antipsychotic agents possessing pro-cognitive properties"],"prefix":"10.1007","volume":"385","author":[{"given":"Jelveh","family":"Lameh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"McFarland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorgen","family":"Ohlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"Ek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Piu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ethan S.","family":"Burstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Tabatabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Risso","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas W.","family":"Bonhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,15]]},"reference":[{"issue":"18","key":"702_CR1","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1517\/14656560802532707","volume":"9","author":"A Abbas","year":"2008","unstructured":"Abbas A, Roth BL (2008) Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders. Expert Opin Pharmacother 9(18):3251\u20133259","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"702_CR2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nn992","volume":"6","author":"SG Anagnostaras","year":"2003","unstructured":"Anagnostaras SG, Murphy GG, Hamilton SE, Mitchell SL, Rahnama NP, Nathanson NM, Silva AJ (2003) Selective cognitive dysfunction in acetylcholine M1 muscarinic receptor mutant mice. Nat Neurosci 6(1):51\u201358. doi: 10.1038\/nn992","journal-title":"Nat Neurosci"},{"key":"702_CR3","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1568007024606249","volume":"1","author":"FP Bymaster","year":"2002","unstructured":"Bymaster FP, Felder C, Ahmed S, McKinzie D (2002) Muscarinic receptors as a target for drugs treating schizophrenia. Curr Drug Targets CNS Neurol Disord 1:163\u2013181","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"3\u20134","key":"702_CR4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1023\/A:1022844517200","volume":"28","author":"FP Bymaster","year":"2003","unstructured":"Bymaster FP, McKinzie DL, Felder CC, Wess J (2003) Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system. Neurochem Res 28(3\u20134):437\u2013442","journal-title":"Neurochem Res"},{"key":"702_CR5","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1192\/bjp.138.1.46","volume":"138","author":"JE Christie","year":"1981","unstructured":"Christie JE, Shering A, Ferguson J, Glen AI (1981) Physostigmine and arecoline: effects of intravenous infusions in Alzheimer presenile dementia. Br J Psychiatry 138:46\u201350","journal-title":"Br J Psychiatry"},{"issue":"5","key":"702_CR6","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S0006-3223(00)00918-5","volume":"48","author":"JM Crook","year":"2000","unstructured":"Crook JM, Tomaskovic-Crook E, Copolov DL, Dean B (2000) Decreased muscarinic receptor binding in subjects with schizophrenia: a study of the human hippocampal formation. Biol Psychiatry 48(5):381\u2013388","journal-title":"Biol Psychiatry"},{"issue":"8","key":"702_CR7","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1038\/sj.npp.1300508","volume":"29","author":"B Dean","year":"2004","unstructured":"Dean B (2004) M1 receptor agonism, a possible treatment for cognitive deficits in schizophrenia. Neuropsychopharmacology 29(8):1583\u20131584. doi: 10.1038\/sj.npp.13005081300508 , author reply 1585\u20131586","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"702_CR8","first-page":"54","volume":"1","author":"B Dean","year":"1996","unstructured":"Dean B, Crook JM, Opeskin K, Hill C, Keks N, Copolov DL (1996) The density of muscarinic M1 receptors is decreased in the caudate-putamen of subjects with schizophrenia. Mol Psychiatry 1(1):54\u201358","journal-title":"Mol Psychiatry"},{"issue":"10","key":"702_CR9","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1038\/sj.mp.4001199","volume":"7","author":"B Dean","year":"2002","unstructured":"Dean B, McLeod M, Keriakous D, McKenzie J, Scarr E (2002) Decreased muscarinic1 receptors in the dorsolateral prefrontal cortex of subjects with schizophrenia. Mol Psychiatry 7(10):1083\u20131091. doi: 10.1038\/sj.mp.4001199","journal-title":"Mol Psychiatry"},{"issue":"1","key":"702_CR10","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0197-4580(80)90022-6","volume":"1","author":"DA Drachman","year":"1980","unstructured":"Drachman DA, Noffsinger D, Sahakian BJ, Kurdziel S, Fleming P (1980) Aging, memory, and the cholinergic system: a study of dichotic listening. Neurobiol Aging 1(1):39\u201343","journal-title":"Neurobiol Aging"},{"issue":"2","key":"702_CR11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1017\/S1461145705005407","volume":"9","author":"JR Ellis","year":"2006","unstructured":"Ellis JR, Ellis KA, Bartholomeusz CF, Harrison BJ, Wesnes KA, Erskine FF, Vitetta L, Nathan PJ (2006) Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. Int J Neuropsychopharmacol 9(2):175\u2013189. doi: 10.1017\/S1461145705005407","journal-title":"Int J Neuropsychopharmacol"},{"issue":"3","key":"702_CR12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.nurt.2008.05.002","volume":"5","author":"A Fisher","year":"2008","unstructured":"Fisher A (2008) Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer\u2019s disease. Neurotherapeutics 5(3):433\u2013442. doi: 10.1016\/j.nurt.2008.05.002","journal-title":"Neurotherapeutics"},{"issue":"1","key":"702_CR13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-004-1794-x","volume":"174","author":"JI Friedman","year":"2004","unstructured":"Friedman JI (2004) Cholinergic targets for cognitive enhancement in schizophrenia: focus on cholinesterase inhibitors and muscarinic agonists. Psychopharmacology (Berl) 174(1):45\u201353. doi: 10.1007\/s00213-004-1794-x","journal-title":"Psychopharmacology (Berl)"},{"key":"702_CR14","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1124\/jpet.107.121715","volume":"322","author":"LR Gardell","year":"2007","unstructured":"Gardell LR, Vanover KE, Pounds L, Johnson RW, Barido R, Anderson GT, Veinbergs I, Dyssegaard A, Brunmark P, Tabatabaei A, Davis RE, Brann MR, Hacksell U, Bonhaus DW (2007) ACP-103, a 5-hydroxytryptamine 2A receptor inverse agonist, improves the antipsychotic efficacy and side-effect profile of haloperidol and risperidone in experimental models. J Pharmacol Exp Ther 322:862\u2013870","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"702_CR15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.bbr.2007.06.012","volume":"184","author":"B Grayson","year":"2007","unstructured":"Grayson B, Idris NF, Neill JC (2007) Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat. Behav Brain Res 184(1):31\u201338. doi: 10.1016\/j.bbr.2007.06.012","journal-title":"Behav Brain Res"},{"key":"702_CR16","first-page":"799","volume":"154","author":"M Green","year":"1996","unstructured":"Green M (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 154:799\u2013804","journal-title":"Am J Psychiatry"},{"key":"702_CR17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/oxfordjournals.schbul.a033430","volume":"26","author":"M Green","year":"2000","unstructured":"Green M, Kern R, Braff D, Mintz J (2000) Neurocognition and functional outcome in schizophrenia: are we measuring the right stuff? Schizoph Bull 26:119\u2013136","journal-title":"Schizoph Bull"},{"key":"702_CR18","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","volume":"45","author":"J Kane","year":"1988","unstructured":"Kane J, Honigfeld G, Singer J, Meltzer HY, Group tCCS (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatr 45:789\u2013796","journal-title":"Arch Gen Psychiatr"},{"key":"702_CR19","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1146\/annurev.med.52.1.503","volume":"52","author":"S Kapur","year":"2001","unstructured":"Kapur S, Remington G (2001) Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 52:503\u2013517. doi: 10.1146\/annurev.med.52.1.503","journal-title":"Annu Rev Med"},{"issue":"1","key":"702_CR20","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bbr.2007.07.033","volume":"186","author":"J Karasawa","year":"2008","unstructured":"Karasawa J, Hashimoto K, Chaki S (2008) d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats. Behav Brain Res 186(1):78\u201383. doi: 10.1016\/j.bbr.2007.07.033","journal-title":"Behav Brain Res"},{"key":"702_CR21","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1073\/pnas.0611417104","volume":"104","author":"S Kim","year":"2007","unstructured":"Kim S, Huang A, Snowman A, Teuscher C, Snyder S (2007) Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Nat Acad Sci 104:3456\u20133459","journal-title":"Proc. Nat. Acad. Sci."},{"key":"702_CR22","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/sj.npp.1300027","volume":"28","author":"WK Kroeze","year":"2003","unstructured":"Kroeze WK, Hufeisen SJ, Popadak BA, Renock SM, Steinberg S, Ernsberger P, Jayathilake K, Meltzer HY, Roth BL (2003) H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharm 28:519\u2013526","journal-title":"Neuropsychopharm"},{"key":"702_CR23","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0022-5347(05)67709-9","volume":"163","author":"H Lepor","year":"2000","unstructured":"Lepor H, Jones K, Williford W (2000) The mechanism of adverse events associated with terazosin: an analysis of the Veterans Affairs cooperative study. J Urol 163:1134\u20131137","journal-title":"J Urol"},{"issue":"10","key":"702_CR24","first-page":"1","volume":"1","author":"Z Li","year":"2005","unstructured":"Li Z, Huang M, Ichikawa J, Dai J, Meltzer HY (2005) N-Desmethylclozapine, a major metabolite of clozapine, increases cortical acetylcholine and dopamine release in vivo via stimulation of M1 muscarinic receptors. Neuropsychopharmacology 1(10):1","journal-title":"Neuropsychopharmacology"},{"key":"702_CR25","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"J Lieberman","year":"2005","unstructured":"Lieberman J, Stroup T, McEvoy J, Swartz M, Rosenheck R, Perkins D, Keefe R, Davis S, Davis C, Lebowitz B, Severe J, Hsiao J, Investigators CAToIEC (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209\u20131223","journal-title":"N Engl J Med"},{"issue":"1","key":"702_CR26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ajmg.b.20020","volume":"119B","author":"D Mancama","year":"2003","unstructured":"Mancama D, Arranz MJ, Landau S, Kerwin R (2003) Reduced expression of the muscarinic 1 receptor cortical subtype in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 119B(1):2\u20136. doi: 10.1002\/ajmg.b.20020","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"7","key":"702_CR27","first-page":"740","volume":"11","author":"RA McArthur","year":"2010","unstructured":"McArthur RA, Gray J, Schreiber R (2010) Cognitive effects of muscarinic M1 functional agonists in non-human primates and clinical trials. Curr Opin Investig Drugs 11(7):740\u2013760","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"702_CR28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-2999(86)90675-8","volume":"123","author":"E Meller","year":"1986","unstructured":"Meller E, Helmer-Matyjek E, Bohmaker K, Adler CH, Friedhoff AJ, Goldstein M (1986) Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists. Eur J Pharmacol 123(2):311\u2013314","journal-title":"Eur J Pharmacol"},{"key":"702_CR29","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-3565(25)20710-8","volume":"251","author":"H Meltzer","year":"1989","unstructured":"Meltzer H, Matsubara S, Lee J (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine, d-1, d-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238\u2013246","journal-title":"J Pharmacol Exp Ther"},{"key":"702_CR30","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S0028-3908(98)00078-1","volume":"37","author":"M Millan","year":"1998","unstructured":"Millan M, Dekeyne A, Gobert A (1998) Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) release and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo. Neuropharmacology 37:953\u2013955","journal-title":"Neuropharmacology"},{"issue":"5","key":"702_CR31","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1124\/mi.5.5.8","volume":"5","author":"KJ Miller","year":"2005","unstructured":"Miller KJ (2005) Serotonin 5-ht2c receptor agonists: potential for the treatment of obesity. Mol Interv 5(5):282\u2013291. doi: 10.1124\/mi.5.5.8","journal-title":"Mol Interv"},{"issue":"2","key":"702_CR32","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s00213-007-0955-0","volume":"196","author":"H Mizoguchi","year":"2008","unstructured":"Mizoguchi H, Takuma K, Fukakusa A, Ito Y, Nakatani A, Ibi D, Kim HC, Yamada K (2008) Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice. Psychopharmacology (Berl) 196(2):233\u2013241. doi: 10.1007\/s00213-007-0955-0","journal-title":"Psychopharmacology (Berl)"},{"key":"702_CR33","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1016\/0024-3205(95)00210-W","volume":"56","author":"C Schmidt","year":"1995","unstructured":"Schmidt C, Sorensen S, Kehne J, Carr A, Palfreyman M (1995) The role of 5-HT2A receptors in antipsychotic activity. Life Sci 56:2209\u20132222","journal-title":"Life Sci"},{"key":"702_CR34","first-page":"55","volume":"7","author":"P Seeman","year":"1992","unstructured":"Seeman P (1992) Elevated D2 in schizophrenia: role of endogenous dopamine and cerebellum. Commentary on \u201cThe current status of PET scanning with respect to schizophrenia\u201d. Neuropsychopharm 7:55\u201357","journal-title":"Neuropsychopharm"},{"issue":"11","key":"702_CR35","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1017\/S1092852900014048","volume":"13","author":"AK Sellin","year":"2008","unstructured":"Sellin AK, Shad M, Tamminga C (2008) Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr 13(11):985\u2013996","journal-title":"CNS Spectr"},{"issue":"8","key":"702_CR36","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","volume":"165","author":"A Shekhar","year":"2008","unstructured":"Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dube S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC (2008) Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia. Am J Psychiatry 165(8):1033\u20131039. doi: 10.1176\/appi.ajp.2008.06091591","journal-title":"Am J Psychiatry"},{"issue":"4352","key":"702_CR37","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1126\/science.351808","volume":"201","author":"N Sitaram","year":"1978","unstructured":"Sitaram N, Weingartner H, Gillin JC (1978) Human serial learning: enhancement with arecholine and choline impairment with scopolamine. Science 201(4352):274\u2013276","journal-title":"Science"},{"issue":"2","key":"702_CR38","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.bbr.2007.10.012","volume":"187","author":"S Snigdha","year":"2008","unstructured":"Snigdha S, Neill JC (2008) Efficacy of antipsychotics to reverse phencyclidine-induced social interaction deficits in female rats\u2014a preliminary investigation. Behav Brain Res 187(2):489\u2013494. doi: 10.1016\/j.bbr.2007.10.012","journal-title":"Behav Brain Res"},{"issue":"6","key":"702_CR39","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1124\/mol.61.6.1297","volume":"61","author":"TA Spalding","year":"2002","unstructured":"Spalding TA, Trotter C, Skjaerbaek N, Messier TL, Currier EA, Burstein ES, Li D, Hacksell U, Brann MR (2002) Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol Pharmacol 61(6):1297\u20131302","journal-title":"Mol Pharmacol"},{"issue":"2","key":"702_CR40","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0022-3565(24)29291-0","volume":"299","author":"KJ Stanhope","year":"2001","unstructured":"Stanhope KJ, Mirza NR, Bickerdike MJ, Bright JL, Harrington NR, Hesselink MB, Kennett GA, Lightowler S, Sheardown MJ, Syed R, Upton RL, Wadsworth G, Weiss SM, Wyatt A (2001) The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat. J Pharmacol Exp Ther 299(2):782\u2013792","journal-title":"J Pharmacol Exp Ther"},{"key":"702_CR41","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrd1956","volume":"5","author":"T Stroup","year":"2006","unstructured":"Stroup T, Alves W, Hamer R, Lieberman J (2006a) Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nature Reviews, Drug Discovery 5:133\u2013146","journal-title":"Nature Reviews, Drug Discovery"},{"key":"702_CR42","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1176\/appi.ajp.163.4.611","volume":"163","author":"T Stroup","year":"2006","unstructured":"Stroup T, Lieberman J, McEvoy J, Swartz M, Davis S, Rosenheck R, Perkins D, Keefe R, Davis C, Severe J, Hsiao J, Investigators C (2006b) Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am J Psychiatry 163:611\u2013622","journal-title":"Am J Psychiatry"},{"key":"702_CR43","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1248\/bpb.22.457","volume":"22","author":"Y Takata","year":"1999","unstructured":"Takata Y, Kurihara J, Suzuki S, Okubo Y, Kato H (1999) A rabbit model for evaluation of chlorpromazine-induced orthostatic hypotension. Biol Pharm Bull 22:457\u2013462","journal-title":"Biol Pharm Bull"},{"issue":"3","key":"702_CR44","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1037\/0735-7044.122.3.570","volume":"122","author":"KE Vanover","year":"2008","unstructured":"Vanover KE, Veinbergs I, Davis RE (2008) Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behav Neurosci 122(3):570\u2013575. doi: 10.1037\/0735-7044.122.3.570","journal-title":"Behav Neurosci"},{"key":"702_CR45","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0022-3565(24)29327-7","volume":"299","author":"DM Weiner","year":"2001","unstructured":"Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohoue E, Hansen HC, Andersson CM, Spalding TA, Gibson DFC, Krebs-Thomson K, Powell SB, Geyey MA, Hacksell U, Brann MR (2001) 5-Hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Therapeut 299:268\u2013276","journal-title":"J Pharmacol Exp Therapeut"},{"key":"702_CR46","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0149-7634(03)00035-6","volume":"27","author":"AH Wong","year":"2003","unstructured":"Wong AH, Tol HHV (2003) Schizophrenia: from phenomenology to neurobiology. Neurosci Biobehav Rev 27:269\u2013306","journal-title":"Neurosci Biobehav Rev"},{"key":"702_CR47","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ddr.1208","volume":"54","author":"MD Wood","year":"2001","unstructured":"Wood MD, Heidbreder C, Reavill C, Ashby CR, Middlemiss DN (2001) 5-HT2C receptor antagonists: potential in schizophrenia. Drug Dev Res 54:88\u201394","journal-title":"Drug Dev Res"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-011-0702-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00210-011-0702-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-011-0702-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T01:30:18Z","timestamp":1741915818000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00210-011-0702-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,15]]},"references-count":47,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1007\/s00210-011-0702-2","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,15]]}}}